McGill University
- Country
- 🇨🇦Canada
- Ownership
- Private
- Established
- 1821-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.mcgill.ca
Clinical Trials
238
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (212 trials with phase data)• Click on a phase to view related trials
Error Augmentation for Upper Limb Rehabilitation in Stroke Survivors
- Conditions
- Stroke
- First Posted Date
- 2025-06-26
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- McGill University
- Target Recruit Count
- 28
- Registration Number
- NCT07039006
- Locations
- 🇨🇦
Jewish Rehabilitation Hospital, Montreal, Quebec, Canada
Music as an Adjunct to Ketamine Therapy for Chronic Pain
- Conditions
- Chronic PainChronic Noncancer Pain
- First Posted Date
- 2025-05-29
- Last Posted Date
- 2025-06-10
- Lead Sponsor
- McGill University
- Target Recruit Count
- 25
- Registration Number
- NCT06994559
- Locations
- 🇨🇦
Montreal General Hospital, Montreal, Quebec, Canada
Evaluating a Mental Health Digital Intervention for Dads
- Conditions
- Mental Health
- First Posted Date
- 2025-03-12
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- McGill University
- Target Recruit Count
- 100
- Registration Number
- NCT06872411
Dietary Protein Requirements in Adults With Facioscapulohumeral Muscular Dystrophy
- Conditions
- Fascioscapulohumeral Muscular Dystrophy
- First Posted Date
- 2025-01-21
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- McGill University
- Target Recruit Count
- 10
- Registration Number
- NCT06785428
- Locations
- 🇨🇦
McGill university, Montréal, Quebec, Canada
Evaluating Knowledge Mobilization Vehicles
- Conditions
- University StudentsDigital InterventionStressCoping
- First Posted Date
- 2025-01-14
- Last Posted Date
- 2025-01-20
- Lead Sponsor
- McGill University
- Target Recruit Count
- 313
- Registration Number
- NCT06773468
- Locations
- 🇨🇦
McGill University, Montréal, Quebec, Canada
- Prev
- 1
- 2
- 3
- 4
- 5
- 47
- Next
News
Epitopea's CryptoMap Platform Identifies Novel Immunotherapy Targets in Melanoma and NSCLC
Epitopea's CryptoMap platform identified 589 non-redundant tumor antigens in cutaneous melanoma and NSCLC, with only 1% derived from mutated sequences.
Novel Nucleus Pulposus Allograft Shows Promise for Chronic Back Pain Treatment
Clinical trials of VIA Disc NP, a minimally invasive treatment using donor nucleus pulposus tissue, demonstrated significant reduction in chronic back pain from 7.1 to 3.8 on a 10-point scale over 12 months.
Lecanemab's Effectiveness for Alzheimer's May Be Significantly Lower in Female Patients, Study Suggests
• Recent analysis of lecanemab (Leqembi) clinical trial data reveals a 31% difference in drug effectiveness between male and female Alzheimer's patients, with men showing a 43% slowing of cognitive decline compared to just 12% in women. • Researchers from McGill University conducted 10,000 simulated trials based on Phase 3 CLARITY AD data, finding the gender disparity occurred randomly in only 12 simulations, suggesting the difference is statistically meaningful. • The findings have significant implications for clinical practice as two-thirds of Alzheimer's patients are female, highlighting the urgent need for sex-specific considerations in both drug development and treatment decisions.
Study Reveals 16% of Phase 2 Cancer Trial Patients Receive Eventually FDA-Approved Drugs
A comprehensive analysis of 2,730 phase 2 cancer trials shows that one in six patients receives treatments that ultimately gain FDA approval, providing important insights for clinical trial recruitment.